Quality of Life (IBS-QOL) measure are limited. The objective of this study was to evaluate the changes from baseline of the IBS-QOL scores, symptom scores and health economic data in IBS patients, after 4 and 8?weeks of treatment with mebeverine hydrochloride or pinaverium bromide. Methods This was a prospective observational cohort study in patients with IBS, diagnosed using the Rome?III criteria in four countries (Poland, Egypt, Mexico and China). Results A total of 607 patients were enrolled. At baseline, the IBS-QOL total scores were 52.0 in Poland, 48.9 in Egypt, 51.9 in Mexico, 76.4 in China and 56.4 overall. Increases in IBS-QOL total score were statistically significant at Weeks?4 and 8 overall and in each country (overall: 11.8 at Week?4, 24.3 at Week?8; p? Conclusions This study demonstrated that IBS patients have a substantially reduced HR-QoL and that treatment with mebeverine hydrochloride or pinaverium bromide improved HR-QoL." />
Quality of Life in Patients with Irritable Bowel Syndrome (IBS), Assessed Using the IBS–Quality of Life (IBS-QOL) Measure After 4 and 8?Weeks of Treatment with Mebeverine Hydrochloride or Pinaverium Bromide: Results of an International Prospective Obs
详细信息    查看全文
  • 作者：Xiaohua Hou (1)
    Shengliang Chen (2)
    Yali Zhang (3)
    Weihong Sha (4)
    Xiaofeng Yu (5)
    Hesham Elsawah (6)
    Afifi Fahmy Afifi (7)
    Hisham Raafat El-Khayat (8)
    Alaa Nouh (9)
    Mohamed Fathalla Hassan (10)
    Ayman Abdel Fatah (11)
    Isabel Rucker Joerg (12)
    Juan Manuel Sánchez Nú?ez (13)
    Rodolfo Osthoff Rueda (14)
    Grazyna Jurkowska (15)
    Michal Walczak (16)
    Ewa Malecka-Panas (17)
    Krzysztof Linke (18)
    Marek Hartleb (19)
    Gwendolyn Janssen-van Solingen (20)
  • 刊名：Clinical Drug Investigation
  • 出版年：2014
  • 出版时间：November 2014
  • 年：2014
  • 卷：34
  • 期：11
  • 页码：783-793
  • 全文大小：337 KB
  • 参考文献：1. Drossman DA, Patrick DL, Whitehead WE, et al. Further validation of the IBS-QOL: a disease–specific, quality–of–life questionnaire. Am J Gastroenterol. 2000;95(4):999-007. CrossRef
    2. Drossman DA, Morris CB, Schneck S, et al. International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit. J Clin Gastroenterol. 2009;43(6):541-0. CrossRef
    3. Kawanawa M, Drossman DA, Shonozaki M, et al. Translation and validation of a Japanese version of the irritable bowel syndrome quality of life measure (IBS-QOL–J). BioPsychoSoc Med. 2007;1:6. CrossRef
    4. Gralnek IM, Hays RD, Kilbourne A, et al. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology. 2000;119:654-0. CrossRef
    5. M?nnikes H, Hecker H, Heymann–M?nnikes I. Predictive factors for therapeutic success in irritable bowel syndrome (IBS) in primary care (PrC) 2001. Z Gastroenterol. p. 39.
    6. Ji HZ, Wu XW, Xu XB, et al. Evaluating the clinical effect and quality of life in the elderly with functional bowel disorders after treatment with pinaverium bromide. J Clin Rehabil Tissue Eng Res. 2007;11(12):2275-.
    7. Patrick DL, Drossman DA, Ihunnaya OF, et al. Quality of life in persons with irritable bowel syndrome. Dig Dis Sci. 1998;43(2):400-1. CrossRef
    8. Winsemius A, Meuwsen IM, Boon C, et al. A pharmacokinetic comparison of the modified release capsule and a plain tablet formulation of mebeverine. Int J Clin Pract. 2002;56:659-2.
    9. MAPI Research Trust. http://www.mapi-trust.org.
    10. Drossman DA, Morris CB, Hu Y, et al. Characterization of health related quality of life (HRQOL) for patients with functional bowel disorder (FBD) and its response to treatment. Am J Gastroenterol. 2007;102:1442-3. CrossRef
    11. Draft guidance for industry on irritable bowel syndrome—clinical evaluation of products for treatment: availability. Federal Register. 2010;75(55):13765-.
    12. Bijkerk CJ, de Wit NJ, Muris JWM, et al. Outcome measures of irritable bowel syndrome: comparison of psychometric and methodological characteristics. Am J Gastroenterol. 2003;98(1):122-. CrossRef
    13. Paré P, Gray J, Lam S, et al. Health-related quality of life, work productivity, and health care utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study. Clin Ther. 2006;28:10. CrossRef
    14. Patel SM, Stason WB, Legedza A, et al. The placebo effect in irritable bowel syndrome trials: a meta-analysis. Neurogastroenterol Motil. 2005;17(3):332-0. CrossRef
    15. Irvine EJ, Whitehead WE, Chey WD, et al. Design of treatment trials for functional gastrointestinal disorders. Gastroenterology. 2006;130:1538-1. CrossRef
  • 作者单位：Xiaohua Hou (1)
    Shengliang Chen (2)
    Yali Zhang (3)
    Weihong Sha (4)
    Xiaofeng Yu (5)
    Hesham Elsawah (6)
    Afifi Fahmy Afifi (7)
    Hisham Raafat El-Khayat (8)
    Alaa Nouh (9)
    Mohamed Fathalla Hassan (10)
    Ayman Abdel Fatah (11)
    Isabel Rucker Joerg (12)
    Juan Manuel Sánchez Nú?ez (13)
    Rodolfo Osthoff Rueda (14)
    Grazyna Jurkowska (15)
    Michal Walczak (16)
    Ewa Malecka-Panas (17)
    Krzysztof Linke (18)
    Marek Hartleb (19)
    Gwendolyn Janssen-van Solingen (20)

    1. Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
    2. Shanghai Renji Hospital, Shanghai, China
    3. Nanfang Hospital, Guangzhou, China
    4. Guangdong General Hospital, Guangzhou, China
    5. Huadong Hospital, Fudan University, Shanghai, China
    6. El-Hourya St. Almaza, Cairo, Egypt
    7. Almoder St. Zgazeg, El Sharkya, Egypt
    8. El-Nile St., Warrak El-Hader, Imbaba, Giza, Egypt
    9. 45 Doki St., Doki Square, Giza, Egypt
    10. Safia Zaghloul St., Portsaid, Egypt
    11. Noor El Islam Private Hospital, Alexandria, Egypt
    12. Clinical Research Institute, Tlalnepantla, Mexico
    13. Privada de Constitución, Guzman Jalizco, Mexico
    14. Torre Medica Tampico, Tampico, Mexico
    15. Praktyka Lekarska ul., Bia?ystok, Poland
    16. NZOZ VITAMED Gastroenterology ul., Bydgoszcz, Poland
    17. Medical University of ?ód?, Lodz, Poland
    18. Gabinet Lekarski Pawe? Klincewicz, ul., Paznań, Poland
    19. Praktyka Lekarska, ul., Katowice, Poland
    20. Abbott Product Operations AG, Allschwil, EPD Headquarters, Hegenheimermattweg 127, 4123, Allschwil, Switzerland
  • ISSN：1179-1918
文摘
Background and Objective Irritable Bowel Syndrome (IBS) has a substantial impact on health-related quality of life (HR-QoL) but high-quality data pre- and post-treatment using the IBS-a href='/search?dc.title=Quality+of+Life&facet-content-type=ReferenceWorkEntry&sortOrder=relevance' class='reference-link webtrekk-track' gaCategory="Internal link" gaLabel="Quality of Life" gaAction="reference keyword">Quality of Life (IBS-QOL) measure are limited. The objective of this study was to evaluate the changes from baseline of the IBS-QOL scores, symptom scores and health economic data in IBS patients, after 4 and 8?weeks of treatment with mebeverine hydrochloride or pinaverium bromide. Methods This was a prospective observational cohort study in patients with IBS, diagnosed using the Rome?III criteria in four countries (Poland, Egypt, Mexico and China). Results A total of 607 patients were enrolled. At baseline, the IBS-QOL total scores were 52.0 in Poland, 48.9 in Egypt, 51.9 in Mexico, 76.4 in China and 56.4 overall. Increases in IBS-QOL total score were statistically significant at Weeks?4 and 8 overall and in each country (overall: 11.8 at Week?4, 24.3 at Week?8; p? Conclusions This study demonstrated that IBS patients have a substantially reduced HR-QoL and that treatment with mebeverine hydrochloride or pinaverium bromide improved HR-QoL.

© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号

地址：北京市海淀区学院路29号 邮编：100083

电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700